Has Joao Nascimento, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,097 in general payments to Joao Nascimento, MD across 234 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joao Nascimento, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joao Nascimento, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joao Nascimento, MD

Rheumatology · Bridgeport, CTNPI 1982616520

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Amgen at 24.3% of the total. Reporting peaked in 2019 at $2,139 and has fallen 96.9% since, to $66 in 2025.

$5,097in general payments, 2019–2025

Across 234 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$1K
Johnson & Johnson$684
UCB, Inc.$524
GSK$505
AbbVie$284
Pfizer$257
plus $2K from 19 others

$25,363in research payments, 2019–2025

Across 5 payments — averaging $5072.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$11K
Astrazeneca UK Limited$9K
GSK$6K

What the payments were for

Food & beverage$4,86595%
Education$2325%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	51	$1,238
Johnson & Johnson(2 entities)	32	$684
UCB, Inc.	18	$524
GSK	26	$505
AbbVie	13	$284
Pfizer	18	$257
Mallinckrodt Hospital Products Inc.	8	$250
Aurinia Pharma U.S., Inc.	6	$157
Sanofi	4	$152
Bristol Myers Squibb	14	$149
Novartis	10	$143
AstraZeneca(2 entities)	4	$95
Lilly USA, LLC	4	$94
Genentech USA, Inc.	6	$88
Regeneron Healthcare Solutions, Inc.	3	$88
Mallinckrodt Enterprises LLC	3	$77
Actelion Pharmaceuticals US, Inc.	2	$62
Merck	4	$61
E.r. Squibb & Sons, L.L.C.	2	$40
Boehringer Ingelheim	1	$34
Radius Health, Inc.	1	$32
Shire North American Group Inc	1	$25
Organon	1	$22
Hikma Pharmaceuticals USA	1	$19
IBSA Pharma Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Enbrel$122

How this compares

$5,097 in reported general payments places this provider in the 70th percentile of 118 rheumatology providers in Connecticut.

See all rheumatology providers in Connecticut →

Medicare billing

Part B allowed, 2024

$632,020

Medicare patients

Services billed

47,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydroxychloroquine Sulfate	16	$315
Prednisone	46	$238
Folic Acid	13	$99

Paid to pharmacies, not to this prescriber.

Other rheumatology in Bridgeport

Kenneth MillerDanbury$873K
Robert SchoenGuilford$638K
Bret SohnStamford$447K
Fotios KoumpourasNorth Haven$314K
James SeiboldFarmington$300K
Michael SpiegelDanbury$215K
John MagaldiTorrington$157K
Archana SharmaBristol$98K
Richard RoseffDanbury$84K
Beth ValashinasOrange$81K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →